Vyas Darshali A, Marinacci Lucas, Bearnot Benjamin, Wakeman Sarah E, Sundt Thoralf M, Jassar Arminder S, Triant Virginia A, Nelson Sandra B, Dudzinski David M, Paras Molly L
Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Open Forum Infect Dis. 2022 Mar 2;9(3):ofac047. doi: 10.1093/ofid/ofac047. eCollection 2022 Mar.
Consensus guidelines recommend multidisciplinary models to manage infective endocarditis, yet often do not address the unique challenges of treating people with drug use-associated infective endocarditis (DUA-IE). Our center is among the first to convene a Drug Use Endocarditis Treatment (DUET) team composed of specialists from Infectious Disease, Cardiothoracic Surgery, Cardiology, and Addiction Medicine.
The objective of this study was to describe the demographics, infectious characteristics, and clinical outcomes of the first cohort of patients cared for by the DUET team. This was a retrospective chart review of patients referred to the DUET team between August 2018 and May 2020 with DUA-IE.
Fifty-seven patients were presented to the DUET team between August 2018 and May 2020. The cohort was young, with a median age of 35, and injected primarily opioids (82.5% heroin/fentanyl), cocaine (52.6%), and methamphetamine (15.8%). Overall, 14 individuals (24.6%) received cardiac surgery, and the remainder (75.4%) were managed with antimicrobial therapy alone. Nearly 65% of individuals were discharged on medication for opioid use disorder, though less than half (36.8%) were discharged with naloxone and only 1 patient was initiated on HIV pre-exposure prophylaxis. Overall, the cohort had a high rate of readmission (42.1%) within 90 days of discharge.
Multidisciplinary care models such as the DUET team can help integrate nuanced decision-making from numerous subspecialties. They can also increase the uptake of addiction medicine and harm reduction tools, but further efforts are needed to integrate harm reduction strategies and improve follow-up in future iterations of the DUET team model.
共识指南推荐采用多学科模式来管理感染性心内膜炎,但往往未涉及治疗药物使用相关感染性心内膜炎(DUA-IE)患者所面临的独特挑战。我们的中心是最早组建药物使用性心内膜炎治疗(DUET)团队的机构之一,该团队由传染病、心胸外科、心脏病学和成瘾医学专家组成。
本研究的目的是描述由DUET团队护理的首批患者队列的人口统计学特征、感染特征和临床结局。这是一项对2018年8月至2020年5月间转诊至DUET团队的DUA-IE患者进行的回顾性病历审查。
2018年8月至2020年5月间,有57名患者被转诊至DUET团队。该队列患者较为年轻,中位年龄为35岁,主要注射阿片类药物(82.5%为海洛因/芬太尼)、可卡因(52.6%)和甲基苯丙胺(15.8%)。总体而言,14名患者(24.6%)接受了心脏手术,其余患者(75.4%)仅接受抗菌治疗。近65%的患者出院时接受了阿片类药物使用障碍药物治疗,但出院时携带纳洛酮的患者不到一半(36.8%),只有1名患者开始接受HIV暴露前预防。总体而言,该队列患者出院后90天内的再入院率较高(42.1%)。
诸如DUET团队这样的多学科护理模式有助于整合众多亚专业的细致决策。它们还可以提高成瘾医学和减少伤害工具的应用,但在DUET团队模式的未来迭代中,需要进一步努力整合减少伤害策略并改善随访。